The Ryanodine Receptor gene (RYR1) and the Calcium Voltage-Gated Channel Subunit Alpha1 S (CACNA1S) gene testing can detect likely causative mutations in roughly 65% of ideal MH test candidates.
  • What is Malignant Hyperthermia Susceptibility (MHS)?

    MHS is a severe adverse reaction to commonly used anesthetics (e.g. halothane, sevoflurane, desflurane, enflurane, isoflurane) or to depolarizing muscle relaxants (e.g. succinylcholine).
    MHS is a pharmacogenomic disorder of calcium regulation in skeletal muscle that can lead to a hypermetabolic response upon exposure to certain environmental factors, including inhaled volatile anesthetics and the muscle relaxant succinylcholine.
    MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine.

  • Symptoms of MHS

    Tachycardia
    Muscle rigidity
    An increase in end-expired carbon dioxide concentration
    Tachypnea
    Hypercapnia
    Rhabdomyolysis
    Death

  • Who Should Get Tested?

    An individual who has an upcoming surgery.
    An individual who has increased sensitivity to caffeine.
    An individual who has increased sensitivity to halothane.
    An individual who has uncontrolled muscle contractions.
    An individual who has skeletal muscle rigidity.
    An individual who has metabolic and respiratory acidosis.
    An individual who has hyperkalemia, hyperthermia, and arrhythmia.
    An individual who has rhabdomyolysis.
    An individual who has experienced an adverse reaction to
    anesthesia.
    An individual who has myopathy, muscular dystrophy or malignant
    hyperthermia.
    An individual who has intolerance to heat.

  • Why Get Tested?

    Help avoid harmful and costly adverse events.
    Reduce death potential associated with certain anesthetics.
    Optimize drug dose.
    Increase chances of treatment success.